Processing...
Clinical Trials for Head And Neck Cancer
Search
Search
There are 219 active trials for advanced/metastatic head and neck cancer.
Click on a trial to see more information.
219 trials meet filter criteria.
Sort by:
HealthScout AI summary: Adults with advanced/metastatic solid tumors or relapsed/refractory non-Hodgkin’s lymphoma (ECOG 0–2) who have exhausted standard options receive once-daily oral APG-5918, an EED inhibitor that allosterically disrupts PRC2 to deplete H3K27me3. Expansion focuses on molecular subsets including EZH2-mutant B‑cell lymphomas, SMARCB1-deficient sarcomas (epithelioid preferred), and castration‑resistant prostate cancer; treated/stable brain mets allowed.
ClinicalTrials.gov ID: NCT05415098
HealthScout AI summary: Children and young adults with relapsed/refractory pediatric-type solid tumors (non-CNS) receive cyclophosphamide/etoposide lymphodepletion followed by a single infusion of ex vivo expanded, cord blood–derived allogeneic NK cells (4–6/6 HLA-matched donor). The NK cells are activated to enhance MHC-unrestricted cytotoxicity (via natural cytotoxicity receptors and ADCC) to assess safety, dosing, persistence, and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT03420963
HealthScout AI summary: Adults with unresectable, locally advanced, or metastatic gastric/GEJ/esophageal or pancreatic adenocarcinoma expressing CLDN18.2 (IHC ≥1+ in ≥50%) receive LB1908, an autologous CLDN18.2-directed CAR-T therapy, as monotherapy in second or later lines or as consolidation after disease control on first-line chemotherapy. Key exclusions include prior cellular/gene therapy, significant effusions/bleeding risk, active autoimmune disease requiring immunosuppression, unstable cardiac/infectious disease, and active CNS disease (except stable treated brain mets in monotherapy cohorts).
ClinicalTrials.gov ID: NCT05539430
HealthScout AI summary: Adults <70 with metastatic gastrointestinal or peritoneal tumors (esophageal, gastric, colorectal, liver, pancreatic) refractory to standard therapy, with at least one lesion amenable to intratumoral injection. Single intratumoral dose of vvDD-hIL2-2-RG-1, an oncolytic vaccinia virus (double-deleted TK/VGF) engineered to express membrane-tethered IL-2 to promote localized T-cell activation and oncolysis; no combination therapy in this first-in-human, single-dose escalation.
ClinicalTrials.gov ID: NCT07001592
HealthScout AI summary: Adults with metastatic or unresectable HER2‑negative adenocarcinoma of the esophagus/GEJ/stomach (no prior metastatic therapy; ECOG 0–2) receive an alternating doublet sFOLFOXIRI schedule: mFOLFOX6 on odd cycles and FOLFIRI on even cycles every 2 weeks. Optional nivolumab (PD‑1 inhibitor) may be added per label to enhance antitumor activity.
ClinicalTrials.gov ID: NCT05332002
HealthScout AI summary: Adults with relapsed/refractory metastatic RCC (clear cell or papillary), EBV-associated NPC, or advanced NHL (including DLBCL, FL, MCL) receive GEN1160 (PRO1160), a CD70-directed antibody–drug conjugate delivering an exatecan topoisomerase-1 inhibitor payload, given IV Day 1 of 21-day cycles; expansion focuses on DLBCL NOS after ≥2 prior regimens including CD20 chemoimmunotherapy. Excludes prior CD70 therapy/topo-1 ADCs, recent transplants/intensive therapy, active CNS disease (expansion), and significant uncontrolled comorbidities.
ClinicalTrials.gov ID: NCT05721222
HealthScout AI summary: Adults with locally advanced/metastatic solid tumors (ECOG 0–1) who have progressed on prior therapy and lack standard options receive SPX‑303 monotherapy, a first‑in‑class bispecific antibody targeting LILRB2 (ILT4) on myeloid cells and PD‑L1, given IV every 3 weeks. Excludes active/unstable CNS disease and prior ILT2/ILT4/HLA‑G–targeted therapy; allows well-controlled HIV.
ClinicalTrials.gov ID: NCT06259552
HealthScout AI summary: Adults with untreated recurrent/metastatic HNSCC (non‑nasopharyngeal) eligible for pembrolizumab are randomized to pembrolizumab alone versus pembrolizumab plus BI 770371 (anti‑SIRPα blocking the CD47–SIRPα “don’t‑eat‑me” axis) with or without cetuximab (anti‑EGFR). Prior definitive therapy is allowed if >6 months from progression; requires measurable disease and tumor tissue, and excludes prior PD‑(L)1 or SIRPα/CD47 agents and active brain metastases.
ClinicalTrials.gov ID: NCT06806852
HealthScout AI summary: Adults with recurrent/metastatic, incurable HNSCC requiring palliative RT and having two index lesions (one for RT, one for serial biopsy) receive pembrolizumab plus the investigational oral AXL/MerTK (TAM) inhibitor INCB081776, with RT delivered to one lesion excluded from efficacy assessments. Suitable for patients recovered from prior therapies, without autoimmune disease requiring immunosuppression or significant retinal disorders.
ClinicalTrials.gov ID: NCT06308913
HealthScout AI summary: Adults with recurrent/metastatic, incurable HNSCC (oral cavity, oropharynx, hypopharynx, larynx, or cervical node with occult primary) who are chemo‑naïve in the R/M setting and not candidates for infusional 5‑FU receive pembrolizumab (anti–PD‑1) plus weekly carboplatin/paclitaxel for six cycles, then pembrolizumab maintenance. Key exclusions include untreated symptomatic CNS mets, active autoimmune disease needing immunosuppression, prior severe hypersensitivity to carboplatin/paclitaxel, and significant uncontrolled comorbidities.
ClinicalTrials.gov ID: NCT04858269